FDA approves Rasonque, a pill that doubled survival rates in advanced pancreatic cancer

The US FDA approved Rasonque, developed by Revolution Medicines, as a new treatment for metastatic pancreatic cancer. The once-daily pill doubled survival rates in a large clinical trial, offering genuine hope to patients who have run out of other options. It marks a significant advance in treating one of oncology's most lethal cancers.

Similar stories

🏥 Health Merck and Moderna mRNA vaccine prevents melanoma recurrence in Phase 3 trial National Geographic PL · 1d ago 🏥 Health Tooth count predicts survival after pancreatic cancer surgery, study finds Science Daily · 4d ago 🔬 Science Scientists engineer probiotic bacteria to fight pancreatic cancer from the inside Science Daily · 7d ago